ASCO 2023 | KarMMa-3: QoL of patients with TCE R/R myeloma treated with ide-cel vs standard regimens
Paula Rodriguez Otero, MD, PhD, University Clinic of Navarra, Pamplona, Spain, comments on the health-related quality of life (QoL) of patients with triple class-exposed (TCE) relapsed/refractory (R/R) multiple myeloma treated with idecabtagene vicleucel (ide-cel) versus standard regimens from the KarMMa-3 (NCT03651128) study. Overall, the study demonstrated a significant improvement in QoL measures in patients treated with ide-cel.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria from lectures: BMS, Janssen, Sanofi, GSK, Amgen, Regeneron and Takeda
Participation in Ad Board meetings: BMS, Janssen, Sanofi, Kite Pharma, Abbvie, Oncopeptides, Takeda, Pfizer and GSK
Consultant: BMS, Abbvie, Roche and Pfizer
Research funding: none
